Analysis of the C/T-1 single nucleotide polymorphism in the CD40 gene in multiple sclerosis

Tissue Antigens

Volumn 68, Issue 4, 2006, Pages 335-338

  Buck, D ^a   Kroner, A ^a   Rieckmann, P ^a   Maurer M ^a   Wiendl, H ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

CD40; Multiple sclerosis; Single nucleotide polymorphism

Indexed keywords

CD40 ANTIGEN; CYTOSINE; THYMINE;

ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CD40 GENE; CELL SURFACE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DNA POLYMORPHISM; FEMALE; GENE; GENE FREQUENCY; GENOTYPE; HETEROZYGOTE; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSTIMULATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; ANTIGENS, CD40; CHILD; CYTOSINE NUCLEOTIDES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; MULTIPLE SCLEROSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; THYMINE NUCLEOTIDES;

EID: 33749562118     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2006.00672.x     Document Type: Article

References (27)

1. Banchereau J, Bazan F, Blanchard D et al. The CD40 antigen and its ligand. Annu Rev Immunol 1994: 12: 881-922.
2. Bishop GA, Hostager BS. Signaling by CD40 and its mimics in B cell activation. Immunol Res 2001: 24: 97-109.
3. Durie FH, Fava RA, Foy TM, Aruffo A, Ledbetter JA, Noelle RJ. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 1993: 261: 1328-30.
4. Gerritse K, Laman JD, Noelle RJ et al. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci U S A 1996: 93: 2499-504.
5. Mohan C, Shi Y, Laman JD, Datta SK. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 1995: 154: 1470-80.
6. Tomer Y, Concepcion E, Greenberg DA. A C/T single-nucleotide polymorphism in the region of the CD40 gene is associated with Graves' disease. Thyroid 2002: 12: 1129-35.
7. Kurylowicz A, Kula D, Ploski R et al. Association of CD40 gene polymorphism (C-1T) with susceptibility and phenotype of Graves' disease. Thyroid 2005: 15: 1119-24.
8. Jacobson EM, Concepcion E, Oashi T, Tomer Y. Graves' disease-associated Kozak sequence single-nucleotide polymorphism enhances the efficiency of CD40 gene translation: a case for translational pathophysiology. Endocrinology 2005: 146: 2684-91.
9. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005: 23: 683-747.
10. Becher B, Dodelet V, Fedorowicz V, Antel JP. Soluble tumor necrosis factor receptor inhibits interleukin 12 production by stimulated human adult microglial cells in vitro. J Clin Invest 1996: 98: 1539-43.
11. Wiendl H, Kieseier BC. Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies. Expert Opin Investig Drugs 2003: 12: 689-712.
12. Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004: 14: 164-74.
13. Berger T, Rubner P, Schautzer F et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003: 349: 139-45.
14. Cepok S, Zhou D, Srivastava R et al. Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest 2005: 115: 1352-60.
15. Ruprecht K, Klinker E, Dintelmann T, Rieckmann P, Gold R. Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology 2004: 63: 1081-3.
16. Keegan M, Konig F, McClelland R et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005: 366: 579-82.
17. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000: 47: 707-17.
18. Cepok S, Rosche B, Grummel V et al. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain 2005: 128: 1667-76.
19. Wandinger K, Jabs W, Siekhaus A et al. Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology 2000: 55: 178-84.
20. Fecteau JF, Neron S. CD40 stimulation of human peripheral B lymphocytes: distinct response from naive and memory cells. J Immunol 2003: 171: 4621-9.
21. Neron S, Racine C, Roy A, Guerin M. Differential responses of human B-lymphocyte subpopulations to graded levels of CD40-CD154 interaction. Immunology 2005: 116: 454-63.
22. Maurer M, Ponath A, Kruse N, Rieckmann P. CTLA4 exon 1 dimorphism is associated with primary progressive multiple sclerosis. J Neuroimmunol 2002: 131: 213-5.
23. Kroner A, Mehling M, Hemmer Bet al. APD-1 polymorphism is associated with disease progression in multiple sclerosis. Ann Neurol 2005: 58: 50-7.
24. Khoury SJ, Sayegh MH. The roles of the new negative T cell costimulatory pathways in regulating autoimmunity. Immunity 2004: 20: 529-38.
25. Polman CH, Killestein J. Anti-myelin antibodies in multiple sclerosis: clinically useful? J Neurol Neurosurg Psychiatr 2006: 77: 712.
26. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005: 202: 473-7.
27. Lennon VA, Wingerchuk DM, Kryzer TJ et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004: 364: 2106-12.